Xanthine oxidoreductase in respiratory and cardiovascular disorders

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 294, Issue 5, 2008, Pages

  Boueiz, Adel ^a   Damarla, Mahendra ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Oxidative stress; Reactive oxygen species; Respiratory diseases; Xanthine dehydrogenase; Xanthine oxidase

Indexed keywords

REACTIVE OXYGEN METABOLITE; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ACUTE LUNG INJURY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEART FAILURE; HYPERTENSION; OXIDATIVE STRESS; PRIORITY JOURNAL; PURINE METABOLISM; REPERFUSION INJURY; RESPIRATORY TRACT DISEASE; REVIEW; ANIMAL; HUMAN; LUNG DISEASE; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LUNG DISEASES; XANTHINE DEHYDROGENASE;

EID: 45849131276     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00007.2008     Document Type: Review

References (118)

1. Abdulnour RE, Peng X, Finigan JH, Han EJ, Hasan EJ, Birukov KG, Reddy SP, Watkins JE 3rd, Kayyali US, Garcia JG, Tuder RM, Hassoun PM. Mechanical stress activates xanthine oxidoreductase through MAP kinase-dependent pathways. Am J Physiol Lung Cell Mol Physiol 291: L345-L353, 2006.
2. Adkins WK, Taylor AE. Role of xanthine oxidase and neutrophils in ischemia-reperfusion injury in rabbit lung. J Appl Physiol 69: 2012-2018, 1990.
3. Ahn SY, Sugi K, Talke P, Theissen JL, Linares HA, Traber LD, Herndon DN, Traber DL. Effects of allopurinol on smoke inhalation in the ovine model. J Appl Physiol 68: 228-234, 1990.
4. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2: 126-130, 2002.
5. Amado LC, Saliaris AP, Raju SV, Lehrke S, St John M, Xie J, Stewart G, Fitton T, Minhas KM, Brawn J, Hare JM. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 39: 531-536, 2005.
6. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107: 1991-1997, 2003.
7. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98: 15215-15220, 2001.
8. Babbar N, Casero RA Jr. Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 66: 11125-11130, 2006.
9. Batist G, Mersereau W, Malashenko BA, Chiu RC. Response to ischemia-reperfusion injury in hypertrophic heart. Role of free-radical metabolic pathways. Circulation 80: III10 -III13, 1989.
10. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353: 2450-2461, 2005.
11. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.
12. Coetzee A, Roussouw G, Macgregor L. Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth 10: 627-633, 1996.
13. Connor N, Williams C, Ciesielski W, Zimmerman J. Global effects of xanthine oxidase stress on alveolar type II cells. Pediatr Crit Care Med 3: 280-287, 2002.
14. Cote CG, Yu FS, Zulueta JJ, Vosatka RJ, Hassoun PM. Regulation of intracellular xanthine oxidase by endothelial-derived nitric oxide. Am J Physiol Lung Cell Mol Physiol 271: L869-L874, 1996.
15. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, Sharma HS, Ceconi C. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 32: 2083-2089, 2000.
16. Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 91: 707-709, 2005.
17. Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112: 1266-1273, 2005.
18. El Solh AA, Saliba R, Bosinski T, Grant BJ, Berbary E, Miller N. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur Respir J 27: 997-1002, 2006.
19. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110: 2175-2179, 2004.
20. Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci USA 97: 10723-10728, 2000.
21. Faggioni R, Gatti S, Demitri MT, Delgado R, Echtenacher B, Gnocchi P, Heremans H, Ghezzi P. Role of xanthine oxidase and reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema. J Lab Clin Med 123: 394-399, 1994.
22. Feng NH, Chu SJ, Wang D, Hsu K, Lin CH, Lin HI. Effects of various antioxidants on endotoxin-induced lung injury and gene expression: mRNA expressions of MnSOD, interleukin-1beta and iNOS. Chin J Physiol 47: 111-120, 2004.
23. Garattini E, Mendel R, Romao MJ, Wright R, Terao M. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372: 15-32, 2003.
24. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91: 749-753, 2005.
25. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500-508, 2005.
26. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des 11: 4145-4151, 2005.
27. Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, Martin TR. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 154: 602-611, 1996.
28. Gori T, Lisi M, Forconi S. Ischemia and reperfusion: the endothelial perspective. A radical view. Clin Hemorheol Microcirc 35: 31-34, 2006.
29. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108: 2034-2040, 2003.
30. Griguer CE, Oliva CR, Kelley EE, Giles GI, Lancaster JR Jr, Gillespie GY. Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res 66: 2257-2263, 2006.
31. Grishko V, Solomon M, Wilson GL, LeDoux SP, Gillespie MN. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell phenotypes. Am J Physiol Lung Cell Mol Physiol 280: L1300-L1308, 2001.
32. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, Channon KM. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26: 333-339, 2006.
33. Haddad IY, Beckman JS, Garver RI, Matalon S. Structural and functional alterations of surfactant protein A by peroxynitrite. Chest 105: 84S, 1994.
34. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol Lung Cell Mol Physiol 265: L555-L564, 1993.
35. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115: 509-517, 2005.
36. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33: 774-797, 2002.
37. Hassoun P, Yu F, Cote C, Zulueta J, Sawhney R, Skinner K, Skinner H, Parks D, Lanzillo J. Upregulation of xanthine oxidase by LPS, interleukin-1, and hypoxia. Am J Respir Crit Care Med 158: 299-305, 1998.
38. Hassoun PM, Yu FS, Shedd AL, Zulueta JJ, Thannickal VJ, Lanzillo JJ, Fanburg BL. Regulation of endothelial cell xanthine dehydrogenase xanthine oxidase gene expression by oxygen tension. Am J Physiol Lung Cell Mol Physiol 266: L163-L171, 1994.
39. Hirano S, Rees RS, Yancy SL, Welsh MJ, Remick DG, Yamada T, Hata J, Gilmont RR. Endothelial barrier dysfunction caused by LPS correlates with phosphorylation of HSP27 in vivo. Cell Biol Toxicol 20: 1-14, 2004.
40. Hoidal JR, Xu P, Huecksteadt T, Sanders KA, Pfeffer K. Transcriptional regulation of human xanthine dehydrogenase/xanthine oxidase. Biochem Soc Trans 25: 796-799, 1997.
41. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90: 1299-1306, 2001.
42. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, Freeman BA. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 274: 4985-4994, 1999.
43. Ichinose M, Sugiura H, Yamagata S, Koarai A, Tomaki M, Ogawa H, Komaki Y, Barnes PJ, Shirato K, Hattori T. Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. Eur Respir J 22: 457-461, 2003.
44. Inoue T, Node K. Vascular failure: a new clinical entity for vascular disease. J Hypertens 24: 2121-2130, 2006.
45. Itoh T, Obata H, Murakami S, Hamada K, Kangawa K, Kimura H, Nagaya N. Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 293: L446-L452, 2007.
46. Jankov RP, Kantores C, Pan J, Belik J. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol 294: L233-L245, 2008.
47. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183-1190, 2003.
48. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 121: 20-24, 1991.
49. Kahl S, Elsasser TH. Endotoxin challenge increases xanthine oxidase activity in cattle: effect of growth hormone and vitamin E treatment. Domest Anim Endocrinol 26: 315-328, 2004.
50. Kao SJ, Su CF, Liu DD, Chen HI. Endotoxin-induced acute lung injury and organ dysfunction are attenuated by pentobarbital anaesthesia. Clin Exp Pharmacol Physiol 34: 480-487, 2007.
51. Kayyali US, Donaldson C, Huang H, Abdelnour R, Hassoun PM. Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia. J Biol Chem 276: 14359-14365, 2001.
52. Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, Hassoun PM. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem 277: 42596-42602, 2002.
53. Kelley EE, Hock T, Khoo NK, Richardson GR, Johnson KK, Powell PC, Giles GI, Agarwal A, Lancaster JR Jr, Tarpey MM. Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells. Free Radic Biol Med 40: 952-959, 2006.
54. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, Li D, Berkowitz DE, Hare JM. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 101: 15944-15948, 2004.
55. Khimenko PL, Taylor AE. Segmental microvascular permeability in ischemia-reperfusion injury in rat lung. Am J Physiol Lung Cell Mol Physiol 276: L958-L960, 1999.
56. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 97: 629-636, 2005.
57. Kocabas E, Sarikcioglu A, Aksaray N, Seydaoglu G, Seyhun Y, Yaman A. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis. Turk J Pediatr 49: 7-20, 2007.
58. Kock R, Delvoux B, Sigmund M, Greiling H. A comparative study of the concentrations of hypoxanthine, xanthine, uric acid and allantoin in the peripheral blood of normals and patients with acute myocardial infarction and other ischaemic diseases. Eur J Clin Chem Clin Biochem 32: 837-842, 1994.
59. Komaki Y, Sugiura H, Koarai A, Tomaki M, Ogawa H, Akita T, Hattori T, Ichinose M. Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulm Pharmacol Ther 18: 297-302, 2005.
60. Kooy NW, Royall JA, Ye YZ, Kelly DR, Beckman JS. Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med 151: 1250-1254, 1995.
61. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115: 135-143, 2007.
62. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, Lapatto R. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 32: 902-906, 1998.
63. Lamb NJ, Gutteridge JM, Baker C, Evans TW, Quinlan GJ. Oxidative damage to proteins of bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome: evidence for neutrophil-mediated hydroxylation, nitration, and chlorination. Crit Care Med 27: 1738-1744, 1999.
64. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27: 943-948, 2007.
65. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18: 858-865, 1997.
66. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 42: 1150-1159, 2003.
67. Liaw WJ, Tzao C, Wu JY, Chen SJ, Wang JH, Wu CC. Inhibition by terbutaline of nitric oxide and superoxide anion levels of endotoxin-induced organs injury in the anesthetized rat. Shock 19: 281-288, 2003.
68. Linder N, Martelin E, Lapatto R, Raivio KO. Posttranslational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions. Am J Physiol Cell Physiol 285: C48-C55, 2003.
69. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 3: 254-267, 2005.
70. Manning AS, Coltart DJ, Hearse DJ. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res 55: 545-548, 1984.
71. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285: H2290-H2297, 2003.
72. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 108: 1315-1325, 1995.
73. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, Berry CE, Barouch LA, Vandegaer KM, Li D, Hare JM. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 98: 271-279, 2006.
74. Minuz P, Fava C, Cominacini L. Oxidative stress, antioxidants, and vascular damage. Br J Clin Pharmacol 61: 774-777, 2006.
75. Miyakawa H, Sato K, Shinbori T, Okamoto T, Gushima Y, Fujiki M, Suga M. Effects of inducible nitric oxide synthase and xanthine oxidase inhibitors on SEB-induced interstitial pneumonia in mice. Eur Respir J 19: 447-457, 2002.
76. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol 19: 488-493, 2004.
77. Montor SG, Thoolen MJ, Mackin WM, Timmermans PB. Effect of azapropazone and allopurinol on myocardial infarct size in rats. Eur J Pharmacol 140: 203-207, 1987.
78. Moores HK, Beehler CJ, Hanley ME, Shanley PF, Stevens EE, Repine JE, Terada LS. Xanthine oxidase promotes neutrophil sequestration but not injury in hyperoxic lungs. J Appl Physiol 76: 941-945, 1994.
79. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551, 1993.
80. Ohtsubo T, Rovira II, Starost MF, Liu C, Finkel T. Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circ Res 95: 1118-1124, 2004.
81. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114, 2006.
82. Page S, Powell D, Benboubetra M, Stevens CR, Blake DR, Selase F, Wolstenholme AJ, Harrison R. Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta 1381: 191-202, 1998.
83. Parker JC, Yoshikawa S. Vascular segmental permeabilities at high peak inflation pressure in isolated rat lungs. Am J Physiol Lung Cell Mol Physiol 283: L1203-L1209, 2002.
84. Parmley LF, Mufti AG, Downey JM. Allopurinol therapy of ischemic heart disease with infarct extension. Can J Cardiol 8: 280-286, 1992.
85. Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, Panetta TF. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 88: 188-191, A186, 2001.
86. Petrishchev NN, Shliakhto EV, Tsyrlin VA, Vlasov TD, Syrenskii AV, Galagudza MM. [The role of oxygen free radicals in the mechanisms of local and distant ischemic myocardial preconditioning]. Vestn Ross Akad Med Nauk 8: 10-15, 2006.
87. Pfeffer KD, Huecksteadt TP, Hoidal JR. Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation. J Immunol 153: 1789-1797, 1994.
88. Pinamonti S, Muzzoli M, Chicca MC, Papi A, Ravenna F, Fabbri LM, Ciaccia A. Xanthine oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease. Free Radic Biol Med 21: 147-155, 1996.
89. Poss WB, Huecksteadt TP, Panus PC, Freeman BA, Hoidal JR. Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am J Physiol Lung Cell Mol Physiol 270: L941-L946, 1996.
90. Pritchard KA Jr, Ou J, Ou Z, Shi Y, Franciosi JP, Signorino P, Kaul S, Ackland-Berglund C, Witte K, Holzhauer S, Mohandas N, Guice KS, Oldham KT, Hillery CA. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol 286: L705-L714, 2004.
91. Quinlan GJ, Lamb NJ, Tilley R, Evans TW, Gutteridge JM. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. Am J Respir Crit Care Med 155: 479-484, 1997.
92. Richard VJ, Murry CE, Jennings RB, Reimer KA. Oxygen-derived free radicals and postischemic myocardial reperfusion: therapeutic implications. Fundam Clin Pharmacol 4: 85-103, 1990.
93. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-e171, 2007.
94. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 353: 1685-1693, 2005.
95. Russell GA, Cooke RW. Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed 73: F27-F31, 1995.
96. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90: 297-304, 2002.
97. Sawyer DB, Colucci WS. Nitric oxide in the failing myocardium. Cardiol Clin 16: 657-664, viii, 1998.
98. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004.
99. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br J Pharmacol 114: 27-34, 1995.
100. Scott JP, Wallwork J. The use of allopurinol in the inhibition of obliterative bronchiolitis of the transplanted lung. Transpl Int 5, Suppl 1: S246-S248, 1992.
101. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschlager N, Hornig B, Drexler H, Harrison DG. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107: 1383-1389, 2003.
102. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 87: 229-234, 2002.
103. Sun R, Wang A, Yan Y, Zhang H. The role of activated neutrophils and free radical in the pathogenesis of pulmonary hypertension. Chin Med Sci J 8: 15-19, 1993.
104. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, Suematsu M, Zweifach BW, Schmid-Schonbein GW. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 95: 4754-4759, 1998.
105. Swei A, Lacy F, Delano FA, Parks DA, Schmid-Schonbein GW. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 6: 179-187, 1999.
106. Taggart DP, Young V, Hooper J, Kemp M, Walesby R, Magee P, Wright JE. Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Br Heart J 71: 177-181, 1994.
107. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 76: 1835-1847, 2005.
108. Turgan N, Boydak B, Habif S, Gulter C, Senol B, Mutaf I, Ozmen D, Bayindir O. Urinary hypoxanthine and xanthine levels in acute coronary syndromes. Int J Clin Lab Res 29: 162-165, 1999.
109. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3: 221-229, 2005.
110. Van Wagoner DR. Molecular basis of atrial fibrillation: a dream or a reality? J Cardiovasc Electrophysiol 14: 667-669, 2003.
111. Wallwork CJ, Parks DA, Schmid-Schonbein GW. Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc Res 66: 30-37, 2003.
112. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349, 2000.
113. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40: 355-360, 2002.
114. Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol Ther 89: 187-206, 2001.
115. Wildhirt SM, Dudek RR, Suzuki H, Bing RJ. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol 50: 253-261, 1995.
116. Wright RM, Ginger LA, Kosila N, Elkins ND, Essary B, McManaman JL, Repine JE. Mononuclear phagocyte xanthine oxidoreductase contributes to cytokine-induced acute lung injury. Am J Respir Cell Mol Biol 30: 479-490, 2004.
117. Yung LM, Leung FP, Yao X, Chen ZY, Huang Y. Reactive oxygen species in vascular wall. Cardiovasc Hematol Disord Drug Targets 6: 1-19, 2006.
118. Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MC. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun 249: 767-772, 1998.